Saturday 17 October 2026
Export GNPX’s income statement to Excel — free account
GENPREX
GNPX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.0% and free cash flow fell 33.0%, each against the same quarter a year earlier.
2.11
0.18
−7.86%
Follow GNPX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
6.76 | 5.61 | 3.84 | 0.67 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.38 | 4.02 | 2.23 | 0.33 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.16 | 0.70 | 1.08 | 0.84 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(10.86) | (9.92) | (96.43) | (92.12) | |
Cash per Share |
32.04 | 57.06 | 184.26 | 31.89 | |
Shareholders Equity per Share |
31.28 | 53.53 | 187.34 | 22.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
31.28 | 53.53 | 187.34 | 22.19 | |
Free Cash Flow |
(5.14) | (3.14) | (4.10) | (3.19) | |
Working Capital |
13.50 | 15.45 | 6.18 | (0.84) | |
Net Current Asset Value |
13.50 | 15.43 | 6.16 | (1.08) | |
| Other line items | |||||
Quick Ratio |
6.47 | 5.38 | 3.60 | 0.43 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(10.86) | (9.92) | (96.43) | (92.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.61 | 1.59 | 0.91 | 1.46 | |
Average Assets |
10.48 | 13.16 | 7.14 | 3.73 | |
Average Common Equity |
8.09 | 10.40 | 4.79 | 1.22 |
Columns are period end dates